SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR.

Authors :: Coates, L.
Landewé, R. B. M.
Mcinnes, I.
Mease, P. J.
Ritchlin, C. T.
Tanaka, Y.
Asahina, A.
Behrens, F.
Gladman, D. D.
Gossec, L.
Gottlieb, A. B.
Warren, R. B.
Ink, B.
Bajracharya, R.
Coarse, J.
Merola, J. F.
Source :: Annals of the Rheumatic Diseases; 2023 Supplement, Vol. 82, p346-347, 2p
Publication Year :: 2023

Full Text Access

Tools